Research Publications

Highland KB, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, Bourdin A Distler, Denton CP, Distler JHW, Hoffmann-Vold, AM, Khanna D, Mayes M, Raghu G, Vonk MC, Gahlemann M, Clerisme-Beaty, E, Girard, M, Stowasser, S, Zoc D, Maher TM, on behalf of the SENSCIS trial investigators. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respiratory Medicine, 2021 Jan;9(1):96-106.

Allanore Y, Bozzi S, Terlinden A, Huscher D, Amand C, Soubrane C, Siegert E, Czirják L, Carreira PE, Hachulla E, Zanatta E, Li M, Airò P, Mendoza FA, Rosato E, Distler O; among the EUSTAR Collaborators: Distler JHW. Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database. Arthritis Res Ther. 2020 Oct 28;22(1):257.

Chakraborty D, Zhu H, Jüngel A, Summa L, Li Y-N, Matei A-E, Zhou X, Huang J, Trinh-Minh T, Chen C-W, Dees C, Bergmann C, Soare A, Ramming A, Schett G, Distler O, Distler JHW. Fibroblast growth factor receptor 3 activates a network of profibrotic signaling pathways to promote fibrosis in Systemic sclerosis. Sci Transl Med. 2020 Sep 30;12(563):eaaz5506.

Hoffmann-Vold AM, Allanore Y, Alves M, Brunborg C, Airó P, Ananieva LP, Czirják L, Guiducci S, Hachulla E, Li M, Mihai C, Riemekasten G, Sfikakis PP, Kowal-Bielecka O, Riccardi A, Distler O; among the EUSTAR Collaborators: Distler JHW. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis. 2020 Sep 28.